Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved NovoRapid er større end risiciene ved behandling af diabetes mellitus.
The Committee for Medicinal products for Human Use (CHMP) decided that NovoRapid’ s benefits are greater than its risks for the treatment of diabetes mellitus.